The Phase 2 grant is for work the company is doing to analyze the proteomic responses of immune cells in patients with Alzheimer's and related conditions.
The UPenn team will collect genetic information from outside patient cohorts, reorganize it in a streamlined process, and provide a database for downstream studies.
The initiative was launched to conduct a large-scale study of cognitive impairment and Alzheimer's disease to advance the discovery of biomarkers of the conditions.